Journal of Stem Cell and Transplantation Biology

A Novel Pre-Vascularized Subcutaneous Site Safely Accommodates Stem Cell Derived Therapies for Treating Diabetes

Download PDF

Published Date: June 13, 2016

A Novel Pre-Vascularized Subcutaneous Site Safely Accommodates Stem Cell Derived Therapies for Treating Diabetes

Gala-Lopez B1,3, Pepper AR1,3, Pawlick RL1, Bruni A1,3, Abualhassan N1,3, Kin T 1,2, Keller G4,5, Nostro MC4,6,7, and Shapiro AMJ1,2,3*

1Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada

2Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada

3Canadian Transplant Research Program (CNTRP)

4McEwen Centre for Regenerative Medicine, Toronto, Ontario, Canada

5Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

6Toronto General Research Institute (TGRI), Toronto, Ontario, Canada

7Department of Physiology, University of Toronto, Toronto, Ontario, Canada

*Corresponding author: A.M. James Shapiro, Clinical Senior Scholar Alberta Innovates - Healthcare Solutions (AIHS), Edmonton, Alberta, Canada, Tel: 780-407-7330; Fax: 780-407-8259; E-mail: amjs@islet.ca

Citation: Gala-Lopez B, Pepper AR, Pawlick RL, Bruni A, Abualhassan N, Kim T, Kin T, et al. (2016) A Novel Pre-Vascularized Subcutaneous Site Safely Accommodates Stem Cell Derived Therapies for Treating Diabetes. J Stem Trans Bio 2(1): 107. Doi: http://dx.doi.org/10.19104/jorm.2017.107

 

Abstract

 

Islet transplantation has become an important treatment modality for Type 1 Diabetes Mellitus (T1DM); nonetheless, the procedure may be limited by donor availability. An alternative has been the increasing use of cellular therapies derived from human Embryonic Stem Cells (hESC), showing very promising results in maturation, yield and ultimately, in insulin secretion in response to adequate stimuli. We recently developed a new technique for cellular transplantation under the skin. This manuscript evaluates the capabilities of the pre-vascularized Device-Less (DL) site to allow transplantation of Pancreatic Endoderm (PE) cells differentiated from hESC to treat diabetes mellitus. Fifty immunodeficient mice, n = 25 diabetic and n = 25 non-diabetic, were transplanted with PE cells. Animals were followed for 22 weeks and grafts were retrieved to evaluate engraftment and subsequent maturation. Diabetic mice showed slightly better engraftment (48% vs. 36%, p = 0.19) and secreted higher concentration of human C-peptide upon glucose stimulation (0.32 ± 0.15 ng/mL vs. 0.13 ± 0.09 ng/mL, p = 0.30), although differences were not significant. This maturation was not sufficient to successfully reverse diabetes. Monomorphic cystic changes were detected in 12% and 8%, respectively (diabetics vs. non-diabetics, p = 0.32) and all grafts seemed to be adequately contained by the surrounding collagen wall within the DL space. Our findings support the capabilities of the DL site to host PE cells and allow safe maturation as a new strategy to treat diabetes.

Keywords: Islet Transplantation; Embryonic Stem Cells; Cell Engraftment; Cell Maturation

Abbreviations

IT: Islet Transplantation; T1DM: Type 1 Diabetes Mellitus; hESC: Human Embryonic Stem Cells; DL: Device-Less; PE: Pancreatic Endoderm; DL: Device-Less; H&E: Hematoxylin and Eosin; STZ: Streptozotocin; SEM: Standard Error of the Mean.

Top ↑

Introduction

 

The recent advances in immunotherapy have allowed Islet Transplantation (IT) to become a mainstay treatment for Type 1 Diabetes Mellitus (T1DM). Today, the procedure is safer and long-term graft survival is comparable to that of pancreas transplant alone, with a reduced risk for complications [1,2]. Nonetheless, the IT procedure is limited by donor availability and usage. Significant variability is associated with this treatment modality and many factors may affect the successful utilization of a donated pancreas. In fact, the entire donation-transplant process depends upon many variables related to the donor clinical characteristics, the type of donation (living, brain death, cardiac death, etc.), the outcomes of islet isolation, and recipient characteristics. As a consequence, the process is not always efficient and like other transplant types, the demand may surpass the available donation pool.

An alternative to IT may be to use renewable sources for insulin secretion from proliferative stem cell populations. In particular, research using insulin-producing cells derived from human embryonic stem cells (hESC) has shown very promising results in maturation yield and ultimately, in insulin secretion in response to adequate stimuli [3-6]. The focus is now on optimizing the existing differentiation protocols to allow for a successful and stable diabetes reversal. However, finding the most efficient transplant site remains a dilemma given the infusion volume needed at the time of transplant and the potential need for graft retrieval in the event of tumor formation [7,8]. These reasons are a deterrent to use the conventional intra portal route for this transplantation modality.

Our group recently described a novel pre-vascularized Device-Less (DL) technique for cell transplantation in the subcutaneous space [9]. This approach was successful in reversing diabetes with mouse and human islets and is currently being used for other cell therapies. We herein describe the use of the DL technique to safely allow engraftment and maturation of Pancreatic Endoderm (PE) cells derived from a hESC line in an experimental xeno-transplant model of diabetes.

Top ↑

Materials and Methods

 

Human Embryonic Stem Cells-derived Pancreatic Endoderm

Pancreatic Endoderm (PE) cells derived from a human embryonic cell line were kindly provided by Drs. M.C. Nostro and G. Keller at the McEwen Centre for Regenerative Medicine in Toronto. Their differentiation protocol uses a combination of cytokines and small molecules to simulate pancreatic development and produces multipotent pancreatic progenitor cells with the potential to differentiate into all pancreatic lineages [10,11]. At the time of transplant, cells were harvested and shipped overnight to Edmonton for immediate implantation.

Transplantation of PE cells

Immunodeficient 8-12 week B6.129S7-Rag1tm1Mom mice (Jackson Laboratory, Bar Harbor, ME, USA) were used for all experiments. Animals (n = 50) were housed under conventional conditions with access to food and water ad libitum and their care was in accordance with guidelines approved by the Canadian Council on Animal Care.

The DL space was created as previously reported by inserting a nylon catheter subcutaneously in the left lower abdomen and left for five weeks before transplant [9].Diabetes was chemically induced by intraperitoneally injecting 180 mg/kg of streptozotocin (STZ; Sigma-Aldrich, ON, Canada) in half of the recipients, one week prior to transplantation. Mice were considered diabetic after two consecutive blood glucose measurements ≥ 11.3 mmol/L (350 mg/dL).

Two groups of mice (diabetics and non-diabetics, n = 25/group) were transplanted with approximately 7×106 PE cells using the DL technique. Animals in the diabetic group also received two consecutive insulin-releasing pellets (LinBit®; LinShin Canada Inc. Toronto, ON, Canada - ~0.1 U insulin/24 hours/30 days) to maintain health for the duration of the study (160 days). A separate group of four mice (two diabetics and two non-diabetics) were transplanted with same amount of PE cells and sacrificed four week post-transplant for early assessment of the graft. All mice were continuously monitored for general health, weight gain and non-fasting blood glucose, as well as the occurrence of tumor formation.

C-peptide Measurements

Blood samples were also obtained at post-transplant week 4, 8, 12, 16, 20 and 22 to quantify stimulated human C-peptide concentration in plasma. Mice from both groups were fasted overnight and whole blood was collected after intraperitoneal injection of glucose (2 g/kg). Quantification of C-peptide was performed using human-specific ultrasensitive ELISA (Mercodia, Uppsala, Sweden. Detection range: 5 - 280 pmol/L (0.015 - 0.85 ng/mL).

Histology

Engrafted cells were analyzed at early (four weeks post-transplant) and at the end of the study. Hematoxylin and eosin (H&E) and Masson’s trichrome stains were used to visualize the grafts on abdominal wall sections and to assess tumor boundaries. Immunofluorescence was used to evaluate endocrine secretory function of long-term engrafted cells using anti-insulin (Dako A0082 – Alexa 568) and anti-glucagon (Abcam – Vector Fl-1000) antibodies. The procedure followed previously established methodology [9] and it included deparaffinization, primary and secondary antibody treatment and counter stain with DAPI (Invitrogen Molecular Probes. Eugene, Oregon). Slides were visualized using a fluorescent microscope with appropriate filters and AxioVision imaging software (Carl Zeiss Microscopy GmbH. Jena, Germany).

Transplantation of Human Islets

In parallel, human islets were transplanted into 8-12 week B6.129S7-Rag1tm1Mom diabetic mice and monitored for 22 weeks to compare human C-peptide secretion levels to those achieved by the study PE cells. The Clinical Islet Transplantation laboratory at the University of Alberta kindly provided human islets after the process of donation, isolation and culture, as reported in previous publications [12]. Permission for these studies was granted by the Health Research Ethics Board of the University of Alberta, Edmonton, Alberta, Canada, and after written permission was obtained from donor families.

Mice were rendered diabetic by intraperitoneal injection of 180 mg/kg streptozotocin (STZ, Sigma-Aldrich, ON, Canada). Animals were considered diabetic after two consecutive blood glucose measurements ≥ 11.3 mmol/L (350 mg/dL). Recipients (n = 6 per group) received 0 IEQ (Sham and STZ), 1,000 IEQ and 3,000 IEQ human islets from three different isolations. Islets from each isolation were randomly allocated to each group and transplanted under the kidney capsule as previously described [13]. Mice in the Sham group were not diabetic and underwent the transplant procedure, but only received a saline solution under the kidney capsule. Animals in the STZ group were chemically-induced diabetics and did not receive transplant, remaining diabetic throughout the entire study.

Animals were periodically monitored for general health, weight and blood glucose until endpoint (22 weeks) when blood samples were taken to determine basal and stimulated human C-peptide levels.

Statistical Analysis

Data are represented as means ± Standard Error of the Mean (SEM). Differences between groups were analyzed using t-test and one-way ANOVA with Tukey’s post-hoc test. Z-score test was used to compare proportions between groups. All comparisons between groups were performed with a 95% confidence interval and a p-value < 0.05 was considered significant. Analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA).

Top ↑

Results

 

A total of 54 mice received 7×106 PE cells/mouse subcutaneously, using the DL technique. Four weeks after transplantation, a viable graft was found in all four sacrificed animals, showing clear features of ductal formations (Figure 1). However, all animals remained diabetic and no detectable human C-peptide was found at this early time point (data not shown).

 

Figure 1: Early (four week) graft visualization with hematoxylin & eosin stain, demonstrating formation of ductal structures (arrows) in the DL space.

 

Twenty weeks after transplantation stimulated C-peptide was detected in both groups and continued to increase until the end of the study. Positive stimulated C-peptide was found in 12 of 25 (48%) mice in the diabetic group vs. 9 of 25 (36%), in non-diabetic (p = 0.19). Mean stimulated C-peptide concentrations at 22 weeks were higher in the diabetic group although differences were not statistically significant (0.32 ± 0.15 ng/mL vs. 0.13 ± 0.09 ng/mL, p = 0.30) (Figure 2A).

 

Figure 2: Stimulated C-peptide secretion from transplanted pancreatic endoderm (PE) cells; A. Secretory profile over time for diabetic and nondiabetic mice, showing detectable C-peptide beyond 20 weeks post-transplant; B. Comparison of C-peptide secretory capabilities of transplanted PE cells vs. human islets at minimal and full dose transplanted in immunodeficient mice. A Sham and STZ (diabetic, non-transplanted) groups are included for comparison and specificity of the assay.

 

As expected, transplants with human islets rapidly reduced blood glycemia in mice, reaching normoglycemia at 12 days (1,000 IEQ) and two days (3000 IEQ), respectively. Animals in the STZ group remained hyperglycemic throughout the study period. When PE transplanted animals were compared to mice receiving a minimal and full mass of human islets the C-peptide secretory profile was significantly reduced (Figure 2B). PE transplanted in diabetic mice secreted on average 0.32 ng/mL, at 22 week of engraftment whereas mice receiving 1,000 IEQ and 3,000 IEQ secreted on average 2.46 ng/mL and 102.7 ng/mL respectively, after the same period of engraftment (p < 0.001). C-peptide levels in both, Sham and STZ groups were under the detection limit for the assay.

By week 22 PE cells were adequately engrafted and endocrine features were detected by immunofluorescence, with positive staining for glucagon and fewer cells containing insulin (Figure 3A-D). Nonetheless, only one mouse in the diabetic group successfully achieved normoglycemia (1/25: 4%). The reduced amount of insulin in these cells contrasted with a significantly higher concentration in engrafted human islets, consistent with blood glucose normalization and positive stimulated C-peptide (Figure 4).

 

Figure 3: Engrafted pancreatic endoderm cells (PE) after 22 weeks of transplantation using the pre-vascularized subcutaneous DL site (Masson’s Trhichrome); A-C Show islet-like cells around a ductal structure; D. Representative immunofluorescent slide staining the graft for glucagon (GcG, green), insulin (red) and DAPI (blue).

 

Figure 4: Comparative endocrine staining of engrafted PE and human islets 22 weeks after transplant. A. Representative immunofluorescent slide of engrafted PE staining for glucagon (GcG, green), insulin (red) and DAPI (blue). B. Representative immunofluorescent slide of human islet graft staining for glucagon (GcG, green), insulin (red) and DAPI (blue)

 

Monomorphic cystic changes were clinically detected in three of 25 (12%) diabetic mice vs. two of 25 (8%) non-diabetics (p = 0.32). All cases presented with simple cysts without any clinical repercussion or malignant teratoma transformation. Upon microscopic examination, all cysts appeared fully surrounded and contained by the collagen wall delimiting the DL space and no ductal or endocrine structures were found outside the DL perimeter (Figure 5).

 

Figure 5: Benign cystic formation in one of the study animals; A and B show developing graft and surrounding tissue in the abdominal wall section. Notice blue collagen wall (arrows) around the DL site perimeter containing cystic structures; C. Corresponding immunofluorescent image of this cyst showing poor staining for endocrine markers at 15 weeks post-transplant.

 

Table 1 summarizes the outcomes of the two study groups marking their corresponding similarities and differences, in terms of secretory function and cyst formation.

 

Table 1: Outcome summary of 50 animals transplanted with insulin-producing pancreatic endoderm (PE) cells. Maturation seems to occur more rapidly in diabetic mice, although differences did not reach statistical significance (95% confidence interval).

 

Top ↑

Discussion

 

Our findings corroborate the utility of the DL technique to facilitate cell therapies. In this case, the aim was to engraft and mature PE cells derived from hESC, and measure indicators towards diabetes reversal.

In our study design we evaluated the potential effect of underlying hyperglycemia for engraftment and maturation of PE cells based on published evidence for accelerated maturation under a chronic hyperglycemic environment [14]. Results confirmed an increased trend in both, maturation and mean concentration of stimulated human C-peptide levels measured at 22 weeks in diabetic mice. Differences however, did not reach statistical significance. C-peptide positive measurements were specific to engrafted cells from human origin, proving to be a valuable tool for assessment of maturation of transplanted PEs.

The process of effective differentiation of hESC is very complex and yet to be fully elucidated. Many authors agree on the multiple hurdles these cells encounter in the process of maturation and only recently, successful in vivo maturation have been reported with adequate glucose-response and occasionally, diabetes reversal [15-19].

Consistent with previous studies, the PE cells we tested in our experiments require a long (more than five months) in vivo maturation period [10,17,20,21].

Despite observing adequate engraftment in almost half of the animals, glucagon staining was predominant in most of the histology samples and positive insulin cells were only occasionally found, which is consistent with the low levels of stimulated c-peptide detected at week 22, as well as failure to correct hyperglycemia. We speculate that longer in vivo maturation or a higher number of hESC-derived PE cells at the time of transplantation may be required to normalize glucose control in diabetic mice, although a more prominent insulin staining has been previously reported when transplanting these cells in the kidney subcapsular space and mammary fat pad [10]. Further experimentation will definitely be required to fully understand the maturation process in this new transplant site.

One of the main limitations for the use of hESC is the inherit risk for teratoma transformation [7]. This is one of the rationales for using alternative transplant sites like the DL technique where a dysfunctional/transforming graft may be easily retrieved. Current differentiation protocols are now focused on producing hESC preparations with a high grade of purity to avoid residual undifferentiated cells, which could potentially lead to tumor formation [22]. In our series of transplants benign monomorphic cystic formations were present in 8 - 12% of cases and no teratoma was detected.

An interesting finding was that resulting cysts were successfully contained by the peripheral collagen wall present in the DL space during the 22-week observation period. This resulted in a restrictive effect similar to that present in other physical devices [14,18]. However, the real restraining capabilities in the settings of a true teratoma formation are still to be proven.

In conclusion, our subcutaneous DL technique has proven to be an adequate host for these human embryonic stem cells - derived pancreatic endoderm, allowing effective engraftment, maturation and added protection against tumor formations. This is certainly an important field of application for this technique and a starting point for further experimentation with improved cell preparation and transplant protocols.

Top ↑

Acknowledgments

 

Boris L. Gala-Lopez is supported through the Izaak Walton Killam Memorial Scholarship, an Alberta Innovated Healthcare Solutions (AIHS) Clinician Fellowship, and from the Canadian National Transplant Research Program (CNRTP). Andrew R. Pepper is supported primarily through a JDRF - Canadian Clinical Trial Network Fellowship, and further supplemented through an AIHS CRIO Team Award (No. 201201154) and the CNTRP. Other funding sources include: the Alberta Diabetes Research Institute Foundation of Canada (DRIFCan), the AIHS Collaborative Research & Innovation Opportunities (CRIO) Team Award, and from the Alberta Diabetes Institute (ADI). A.M. James Shapiro is supported through a Canada Research Chair in Transplantation Surgery and Regenerative Medicine and through AIHS as a Senior Scholar. A.M. James Shapiro is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Top ↑

References

 

  1. Shapiro AM. Immune antibody monitoring predicts outcome in islet transplantation. Diabetes. 2013;62(5):1377-8. doi:10.2337/db13-0019.
  2. Pepper AR, Gala-Lopez B, Ziff O, Shapiro AM. Current status of clinical islet transplantation. World J Transplant. 2013;3(4):48-53. doi:10.5500/wjt.v3.i4.48.
  3. Hua XF, Wang YW, Tang YX, Yu SQ, Jin SH, Meng XM, et al. Pancreatic insulin-producing cells differentiated from human embryonic stem cells correct hyperglycemia in SCID/NOD mice, an animal model of diabetes. PloS one. 2014;9(7):e102198. doi:10.1371/journal.pone.0102198.
  4. Gioviale MC, Bellavia M, Damiano G, Lo Monte AI. Beyond islet transplantation in diabetes cell therapy: from embryonic stem cells to transdifferentiation of adult cells. Transplant Proc. 2013;45(5):2019-24. doi: 10.1016/j.transproceed.2013.01.076.
  5. Bose B, Shenoy SP, Konda S, Wangikar P. Human embryonic stem cell differentiation into insulin secreting beta-cells for diabetes. Cell Biol Int. 2012;36(11):1013-20. doi: 10.1042/CBI20120210.
  6. Hrvatin S, O'Donnell CW, Deng F, Millman JR, Pagliuca FW, DiIorio P, et al. Differentiated human stem cells resemble fetal, not adult, beta cells. Proc Natl Acad Sci U S A. 2014;111(8):3038-43. doi: 10.1073/pnas.1400709111.
  7. McCall MD, Toso C, Baetge EE, Shapiro AM. Are stem cells a cure for diabetes? Clin Sci (Lond). 2009;118(2):87-97. doi: 10.1042/CS20090072.
  8. Pepper AR, Gala-Lopez B, Ziff O, Shapiro AM. Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol. 2013;2013:352315. doi: 10.1155/2013/352315.
  9. Pepper AR, Gala-Lopez B, Pawlick R, Merani S, Kin T, Shapiro AM. A prevascularized subcutaneous device-less site for islet and cellular transplantation. Nat Biotechnol. 2015;33(5):518-23. doi: 10.1038/nbt.3211.
  10. Nostro MC, Sarangi F, Yang C, Holland A, Elefanty AG, Stanley EG, et al. Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem Cell Reports. 2015;4(4):591-604. doi: 10.1016/j.stemcr.2015.02.017.
  11. Korytnikov R, Nostro MC. Generation of polyhormonal and multipotent pancreatic progenitor lineages from human pluripotent stem cells. Methods. 2016;101:56-64. doi: 10.1016/j.ymeth.2015.10.017.
  12. Gala-Lopez BL, Pepper AR, Pawlick RL, O'Gorman D, Kin T, Bruni A, et al. Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. Diabetes. 2016;65(2):451-62. doi: 10.2337/db15-0764.
  13. Dong-sheng Li, Jianqiang Hao, Ya-Hong Yuan, Se Hak Yun, Jing-Bo Feng, Long-Jun Dai et al. Pancreatic islet transplantation to the renal subcapsule in mice. Protocol Exchange. 2011. doi:10.1038/protex.2011.221.
  14. Bruin JE, Rezania A, Xu J, Narayan K, Fox JK, O'Neil JJ, et al. Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia. 2013;56(9):1987-98. doi:10.1007/s00125-013-2955-4.
  15. Nostro MC, Keller G. Generation of beta cells from human pluripotent stem cells: Potential for regenerative medicine. Semin Cell Dev Biol. 2012;23(6):701-10. doi: 10.1016/j.semcdb.2012.06.010.
  16. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159(2):428-39. doi: 10.1016/j.cell.2014.09.040.
  17. Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121-33. doi: 10.1038/nbt.3033.
  18. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392-401.
  19. Russ HA, Parent AV, Ringler JJ, Hennings TG1, Nair GG, Shveygert M, et al. Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 2015;34(13):1759-72. doi: 10.15252/embj.201591058.
  20. Rezania A, Bruin JE, Riedel MJ, Mojibian M, Asadi A, Xu J, et al. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes. 2012;61(8):2016-29. doi:10.2337/db11-1711.
  21. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26(4):443-52. doi: 10.1038/nbt1393.
  22. Cunningham JJ, Ulbright TM, Pera MF, Looijenga LH. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol. 2012;30(9):849-57.

Top ↑

Copyright: © 2016 Gala-Lopez B, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.